Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity.

MLA

Anderson, Kimberly E., et al. “Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity.” ACS Chemical Biology, vol. 12, no. 10, Oct. 2017, pp. 2522–28. EBSCOhost, https://doi.org/10.1021/acschembio.7b00711.

APA

Anderson, K. E., To, M., Olzmann, J. A., & Nomura, D. K. (2017). Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity. ACS Chemical Biology, 12(10), 2522–2528. https://doi.org/10.1021/acschembio.7b00711

Chicago

Anderson, Kimberly E, Milton To, James A Olzmann, and Daniel K Nomura. 2017. “Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity.” ACS Chemical Biology 12 (10): 2522–28. doi:10.1021/acschembio.7b00711.